Preliminary Clinical Study of Aclacinomycin A

  • Hisashi Majima
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 70)


Aclacinomycin A (ACM), a new anthracycline antitumor antibiotic, was isolated in 1974 from a culture of Streptomyces galiaeus MA144-MI by Dr. Umezawa et al. in Japan [3]. The structure of ACM is characterized by an ethyl group at position C-13, methyloxy-carbonyl group at C-10, and rhodosamine, 2-deoxyfucose, and cinerulose at position C-7 (Fig. 1).


Toxicity Lymphoma Cobalt Bilirubin Streptomyces 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Furue, H., et al.: Clinical experience with aclacinomycin A. Cancer Chemother. 4, 75 (1977)Google Scholar
  2. 2.
    Oki, T., et al.: Production of nineteen anthracyclic compounds by Streptomyces galilaeus MA 144-M1. J. Antibiot. (Tokyo) 30, 683 (1977)Google Scholar
  3. 3.
    Umezawa, H., et al: New antitumor antibiotics, aclacinomycin A and B. J. Antibiot. (Tokyo). 28, 830 (1975)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • Hisashi Majima
    • 1
  1. 1.Medical Oncology DivisionChiba Cancer Center HospitalChiba 280Japan

Personalised recommendations